Literature DB >> 15464054

Opioid control of MAP kinase cascade.

Rüdiger Schulz1, Daniela A Eisinger, Andrea Wehmeyer.   

Abstract

Activation of G protein-coupled receptors (GPCRs) may result in phosphorylation of extracellular signal-regulated kinases 1/2 (ERK 1/2). The signaling pathway involves ectodomain shedding, generating epidermal growth factor (EGF)-like ligands, which in turn stimulate the mitogen-activated protein kinase (MAPK) via EGF receptors. The present study investigates into the control of MAPKs by opioidergic GPCRs in human embryonic kidney cells (HEK 293). Experiments were conducted with cells expressing opioid receptors, G protein-coupled receptor kinases, and ERKs. The outcome of our studies let us suggest that EGF-like ligands released by opioid receptor stimulation utilize different EGF receptors to phosphorylate ERKs, while EGF utilizes type 1 receptors. Differences between multiple opioid receptors are apparent with respect to the activation of ERKs. EGF rapidly triggers internalization of the fluorescent EGF receptor type 1, but we failed to observe any sequestration of this receptor type upon exposure of cells to an opioid, since opioids most likely trigger stimulation of a different EGF receptor type. In conclusion, G protein-coupled opioid receptors control the MAPK cascade in a similar fashion as described for non-opioid GPCRs, although distinct differences exist between mu-, delta- and kappa-receptors. EGF-induced ERK activation is mediated by EGF receptor type 1 while opioid receptor activation seems to brings about stimulation via EGF receptor type.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464054     DOI: 10.1016/j.ejphar.2004.07.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons.

Authors:  Tara A Macey; Janet D Lowe; Charles Chavkin
Journal:  J Biol Chem       Date:  2006-09-18       Impact factor: 5.157

2.  Gene expression changes following extinction testing in a heroin behavioral incubation model.

Authors:  Kara L Kuntz-Melcavage; Robert M Brucklacher; Patricia S Grigson; Willard M Freeman; Kent E Vrana
Journal:  BMC Neurosci       Date:  2009-08-07       Impact factor: 3.288

3.  Identification of candidate genes and gene networks specifically associated with analgesic tolerance to morphine.

Authors:  Jenica D Tapocik; Noah Letwin; Cheryl L Mayo; Bryan Frank; Troung Luu; Ovokeraye Achinike; Carrie House; Russell Williams; Greg I Elmer; Norman H Lee
Journal:  J Neurosci       Date:  2009-04-22       Impact factor: 6.167

4.  Role for engagement of β-arrestin2 by the transactivated EGFR in agonist-specific regulation of δ receptor activation of ERK1/2.

Authors:  Le-Sha Zhang; Yu-Jun Wang; Yun-Yue Ju; Gui-Ying Zan; Chi Xu; Min-Hua Hong; Yu-Hua Wang; Zhi-Qiang Chi; Jing-Gen Liu
Journal:  Br J Pharmacol       Date:  2015-09-23       Impact factor: 8.739

5.  Regulation of neuronal PLCgamma by chronic morphine.

Authors:  Daniel H Wolf; Eric J Nestler; David S Russell
Journal:  Brain Res       Date:  2007-05-04       Impact factor: 3.252

6.  Morphine-induced MOR-1X and ASF/SF2 Expressions Are Independent of Transcriptional Regulation: Implications for MOR-1X Signaling.

Authors:  Patrick M Regan; Ilker K Sariyer; T Dianne Langford; Prasun K Datta; Kamel Khalili
Journal:  J Cell Physiol       Date:  2015-12-28       Impact factor: 6.384

Review 7.  Opioids: Modulators of angiogenesis in wound healing and cancer.

Authors:  Martina Ondrovics; Andrea Hoelbl-Kovacic; Daniela Alexandra Fux
Journal:  Oncotarget       Date:  2017-04-11

8.  Oxycodone self-administration activates the mitogen-activated protein kinase/ mitogen- and stress-activated protein kinase (MAPK-MSK) signaling pathway in the rat dorsal striatum.

Authors:  Christopher A Blackwood; Michael T McCoy; Bruce Ladenheim; Jean Lud Cadet
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.996

9.  Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.

Authors:  Inka Regine Weingaertner; Sarah Koutnik; Hermann Ammer
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.